TMBR
Income statement / Annual
Last year (2022), Timber Pharmaceuticals, Inc.'s total revenue was $83,177.00,
a decrease of 71.87% from the previous year.
In 2022, Timber Pharmaceuticals, Inc.'s net income was -$19.38 M.
See Timber Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
01/31/2020 |
01/31/2019 |
01/31/2018 |
01/31/2017 |
01/31/2016 |
12/31/2014 |
09/30/2013 |
| Operating Revenue |
$83,177.00 |
$295,738.00 |
$453,810.00 |
$324,646.00 |
$57,000.00 |
$73,000.00 |
$100,000.00 |
$64,000.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$13.30 M
|
$6.15 M
|
$1.50 M
|
$3.38 M
|
$83,000.00
|
$250,000.00
|
$516,000.00
|
$237,000.00
|
$0.00
|
$0.00
|
| Gross Profit |
-$13.22 M
|
-$5.85 M
|
-$1.05 M
|
-$3.06 M
|
-$26,000.00
|
-$177,000.00
|
-$416,000.00
|
-$173,000.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
-158.92
|
-19.79
|
-2.31
|
-9.42
|
-0.46
|
-2.42
|
-4.16
|
-2.7
|
0
|
0
|
| Research and Development Expenses |
$13.30 M
|
$6.15 M
|
$15.10 M
|
$3.38 M
|
$9.08 M
|
$9.14 M
|
$10.16 M
|
$5.70 M
|
$0.00
|
$0.00
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.24 M
|
$5.14 M
|
$4.65 M
|
$4.17 M
|
$0.00
|
$52,305.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$2.16 M
|
$2.42 M
|
$3.20 M
|
$5.11 M
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$6.02 M
|
$5.39 M
|
$4.06 M
|
$586,559.00
|
$7.40 M
|
$7.56 M
|
$7.85 M
|
$9.28 M
|
$0.00
|
$52,305.00
|
| Other Expenses |
-$83,177.00
|
-$590,794.00
|
-$453,810.00
|
$0.00
|
$0.00
|
$0.00
|
-$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$19.24 M
|
$10.95 M
|
$18.71 M
|
$586,715.00
|
$16.48 M
|
$16.70 M
|
$18.01 M
|
$14.99 M
|
$0.00
|
$52,305.00
|
| Cost And Expenses |
$19.24 M
|
$10.95 M
|
$18.71 M
|
$3.97 M
|
$16.56 M
|
$16.95 M
|
$18.53 M
|
$15.22 M
|
$0.00
|
$52,305.00
|
| Interest Income |
$2,445.00
|
$15,551.00
|
$816,657.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.00
|
| Interest Expense |
$228,456.00
|
$15,551.00
|
$4.42 M
|
$0.00
|
$28,000.00
|
$364,000.00
|
$163,000.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$77,445.00
|
$272,882.00
|
$2.43 M
|
$171,860.00
|
$62,000.00
|
$52,000.00
|
$260,000.00
|
$86,000.00
|
$0.00
|
$0.00
|
| EBITDA |
-$19.16 M |
-$10.38 M |
-$17.78 M |
-$45,558.00 |
-$17.17 M |
-$16.88 M |
-$17.98 M |
-$15.16 M |
$0.00 |
-$52,305.00 |
| EBITDA Ratio |
-230.33
|
-36.01
|
-39.17
|
-0.14
|
-301.16
|
-327.18
|
-179.81
|
-242.31
|
0
|
0
|
| Operating Income Ratio |
-231.26
|
-36.01
|
-44.54
|
-11.23
|
-302.25
|
-327.89
|
-182.41
|
-243.66
|
0
|
0
|
| Total Other Income/Expenses Net |
-$136,454.00
|
-$19,170.00
|
$5.13 M
|
-$156.00
|
-$750,000.00
|
$238,000.00
|
-$163,000.00
|
-$436,000.00
|
$0.00
|
$1.00
|
| Income Before Tax |
-$19.37 M
|
-$10.67 M
|
-$15.08 M
|
-$3.64 M
|
-$17.26 M
|
-$16.64 M
|
-$18.40 M
|
-$15.59 M
|
$0.00
|
-$52,304.00
|
| Income Before Tax Ratio |
-232.9
|
-36.08
|
-33.23
|
-11.23
|
-302.74
|
-227.92
|
-184.04
|
-243.66
|
0
|
0
|
| Income Tax Expense |
$7,600.00
|
-$30,242.00
|
$37,842.00
|
-$156.00
|
$2,000.00
|
-$7.66 M
|
$2,000.00
|
$4,000.00
|
$0.00
|
$0.00
|
| Net Income |
-$19.38 M
|
-$10.64 M
|
-$15.12 M
|
-$3.69 M
|
-$17.26 M
|
-$8.98 M
|
-$18.41 M
|
-$15.60 M
|
$0.00
|
-$52,304.00
|
| Net Income Ratio |
-232.99
|
-35.97
|
-33.31
|
-11.37
|
-302.77
|
-122.99
|
-184.06
|
-243.72
|
0
|
0
|
| EPS |
-9.19 |
-13.15 |
-48.15 |
-29.31 |
-1340.11 |
-1567.94 |
-7710.93 |
-13030.91 |
0 |
-0.0058 |
| EPS Diluted |
-9.19 |
-13.15 |
-48.15 |
-29.31 |
-1340.11 |
-1567.94 |
-7710.93 |
-13030.91 |
0 |
-0.0058 |
| Weighted Average Shares Out |
$2.11 M
|
$808,811.00
|
$313,997.00
|
$125,914.00
|
$12,878.00
|
$5,726.00
|
$2,387.00
|
$1,197.00
|
$204,340.00
|
$9.00 M
|
| Weighted Average Shares Out Diluted |
$2.11 M
|
$808,811.00
|
$313,997.00
|
$125,914.00
|
$12,878.00
|
$5,726.00
|
$2,387.00
|
$1,197.00
|
$204,340.00
|
$9.00 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
